| P50 | author | Richie Soong | Q39459426 |
| P2093 | author name string | Nur Sabrina Sapari | |
| | Boon-Cher Goh | |
| | Gaik Hong Soon | |
| | Kok-Yong Seng | |
| | Lawrence Soon-U Lee | |
| | Kim-Hor Hee | |
| P2860 | cites work | Genetic contribution to variable human CYP3A-mediated metabolism | Q28212042 |
| | Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam | Q28305304 |
| | PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. | Q33219671 |
| | Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes | Q33914036 |
| | A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model | Q34337705 |
| | The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA Perspective | Q35129048 |
| | Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients | Q35825212 |
| | Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. | Q35825944 |
| | Prolonged sedation due to accumulation of conjugated metabolites of midazolam | Q42276898 |
| | Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions | Q42578169 |
| | Metabolism of 1'- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7. | Q42936096 |
| | Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects | Q44870135 |
| | CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. | Q44922994 |
| | Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration | Q45247227 |
| | Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo | Q46496009 |
| | Characterization of 1'-hydroxymidazolam glucuronidation in human liver microsomes | Q46903207 |
| | A size standard for pharmacokinetics. | Q47332170 |
| | Factors affecting cytochrome P-450 3A activity in cancer patients. | Q47873497 |
| | Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation | Q48567513 |
| | Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. | Q48589806 |
| | Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug | Q48706686 |
| | Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. | Q51635996 |
| | Clinical pharmacokinetics of midazolam in intensive care patients, a wide interpatient variability? | Q51774518 |
| | Failure of critically ill patients to metabolise midazolam. | Q51789578 |
| | The pharmacokinetics of midazolam in man. | Q51868900 |
| | Akaike's information criterion in generalized estimating equations. | Q52066951 |
| P433 | issue | 2 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| | midazolam | Q423071 |
| P304 | page(s) | 215-224 | |
| P577 | publication date | 2013-12-17 | |
| P1433 | published in | The Journal of Clinical Pharmacology | Q7743562 |
| P1476 | title | CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients | |
| P478 | volume | 54 | |